Although several DPP4 inhibitors such as sitagliptin (MK-0431) (Kim et al., 2005), vildagliptin (LAF-237) (Villhauer et al., 2003), saxagliptin (BMS-477118) (Augeri et al., 2005), alogliptin (SYR-322) (Feng et al., 2007) and linagliptin (BI-1356) (Eckhardt et al., 2007) have been approved for the treatment of T2DM, few natural compounds have been reported to exert DPP4 inhibitory activity (Geng et al., 2013). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.